AHFS® Drug Information® 2022 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.
AHFS Drug Information 2022 is not available as an eBook. Learn more about related resources, electronic only monographs, and AHFS® Clinical Drug InformationTMhere.
With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS®DI® helps you protect your patients and your practice.
New in 2022:
The latest information on COVID-19 vaccines and COVID-19 monoclonal antibodies available under FDA Emergency Use Authorizations (EUAs), including clinical considerations from the US Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH)
Information on patient selection and appropriate use of corticosteroids in the management of COVID-19 based on recent guidelines from NIH and the World Health Organization (WHO)
Contemporary issues such as anticoagulant reversal strategies and use of direct oral anticoagulants versus warfarin for treatment of venous thromboembolism or atrial fibrillation
Current best practices such as reversal of neuromuscular blocking agents for prevention of postoperative residual neuromuscular blockade
Newly published information on breakthrough oncology drugs approved as part of the FDA’s accelerated approval program
Expanded content on off-label uses, real-world data, and long-term clinical data
Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
Addition of 51 new molecular entities (NMEs) or new therapeutic biological products approved since January 2021
Published by Authority of the Board of the AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS®
American Hospital Formulary Service®
Vice President, Publishing Office: Daniel J. Cobaugh, PharmD, DABAT, FAACT
Deputy Editors-in-Chief: Shingyee Cindy Huang, PharmD and Lily L. Leu, PharmD, BCOP
Principal Editorial Contributors: University of Illinois at Chicago Drug Information Service and University of Utah Drug Information Service
Editorial Contributors: Linda Bedford Arcuri, PharmD, and Susan K. Braun, BSPharm
Contributors: University of Arizona, University of Missouri, Kansas City, and Lindsey R. Harper, PharmD
Assistant Editor for Injectables: Natalie C. Rosanelli, PharmD
Director of Clinical Informatics: Seth A. Strawbridge, PharmD
Project Manager: Elizabeth P. Shannon, BS
“AHFS DI has maintained itself as a premier, evidence-based drug compendium. Even in the era of digital, online use, AHFS DI has evolved . . . and offers its information both in print and online.
What sets AHFS DI apart from the [other drug information books available] is its comparative, unbiased, evaluative drug information and its continually maintained relevance. It has been vetted through multiple channels of review and has consistently been recognized as the gold standard of where to obtain drug information.”
Patrick J. Scoble, PharmD, 2021
"This book succeeds in offering an updated drug compendium of evidence-based drug monographs, meeting the needs of today's healthcare professionals. The reference continues to be trustworthy, relying on the most prestigious and knowledgeable drug experts in the medical field.
This reference can be used by any healthcare professional utilizing or prescribing medications in their practice, including physicians, pharmacists, physician assistants, and nurse practitioners. The book is so nicely organized and easily referenced that it can also be used by students in the medical, pharmacy, and nursing fields as well."